RE:RE:RE:RE:we would need 4 more people like lynne gagnon
Stockman I agree 100%... but I agree with Aureus that Gagnon should never see the inside of an investors presentation again! Major fail. She should stick to lab rats and cashing in on those $0.12 options. Time to hire someone on the corporate side who can actually deliver a polished presentation and get the current projects out of the lab and into the pharmacy.
As for the "long list of indications for 4050" - I don't believe the hype AT ALL. We're years away from getting the first 4050 indication to market, so if Pierre et al believe they can trick me anymore into buying into the song and dance that are the "other indications" - that ship has sailed with his credibility. FOCUS on what we're doing and save the fluff for Gagnon etc in the labs until you can produce something concrete. That stuff is nothing more than dangling carrots no less than 5+ years from commercialization with a % likelihood of commercial success close to zero at this stage.